RT @AkhilSoodMD: Abs 0463 #ACR21 @RheumNow Park & colleagues compared treatment persistence across abatacept, TNFi,
Tweet Content
Abs 0463 #ACR21 @RheumNow
Park & colleagues compared treatment persistence across abatacept, TNFi, and JAKi in dual seropositive RA patients using Medicare database
- Users of abatacept were more persistent to index time of 12 months and showed longer time to discontinuation https://t.co/0huE7zZjLq
Show on Archive Page
On
Display in Search Results
On
PDQ
Off